Kir2.2 p.Thr140Met: a genetic susceptibility to sporadic periodic paralysis

CHUNXIANG FAN1*, MARIUS KUHN2*, ALEXANDER PEPLER MBiol3, JAMES GROOME4, VERN WINSTON4, SASKIA BISKUP3, FRANK LEHMANN-HORN1** and KARIN JURKAT-ROTT

1 Division of Neurophysiology, Ulm University, Germany; 2 Genetikum, Neu-Ulm, Germany; 3 CeGaT GmbH, Tübingen, Germany; 4 Department of Biological Sciences, Idaho State University, Pocatello, USA

Introduction. Periodic paralyses (PP) are recurrent episodes of flaccid limb muscle weakness. Next to autosomal dominant forms, sporadic PP (SPP) cases are known but their genetics are unclear.

Methods. In a patient with hypokalemic SPP, we performed exome sequencing to identify a candidate gene. We sequenced this gene in 263 unrelated PP patients without any known causative mutations. Then we performed functional analysis of all variants found and molecular modelling for interpretation.

Results. Exome sequencing in the proband yielded three heterozygous variants predicted to be linked to disease. These encoded p.Thr140Met in the Kir2.2 potassium channel, p.Asp229Asn in protein kinase C theta, and p.Thr15943Ile in titin. Since all hitherto known causative PP genes code for ion channels, we studied the Kir2.2-encoding gene, KCNJ12, for involvement in PP pathogenesis. KCNJ12 screening in 263 PP patients revealed three further variants, each in a single individual and coding for p.Gly419Ser, p.Cys75Tyr, and p.Ile283Val. All four Kir2.2 variants were functionally expressed. Only p.Thr140Met displayed relevant functional alterations, i.e. homo-tetrameric channels produced almost no current, and hetero-tetrameric channels suppressed co-expressed wildtype Kir2.1 in a dominant-negative manner. Molecular modelling showed Kir2.2 p.Thr140Met to reduce movement of potassium ions towards binding sites in the hetero-tetramer pore compatible with a reduced maximal current. MD simulations revealed loss of hydrogen bonding with the p.Thr140Met substitution.

Discussion. The electrophysiological findings of p.Thr140Met are similar to those found in thyrotoxic PP caused by Kir2.6 mutations. Also, the homologous Thr140 residue is mutated in Kir2.6. This supports the idea that Kir2.2 p.Thr140Met conveys susceptibility to SPP and should be included in genetic screening.

Key words: periodic paralysis, susceptibility gene, Kir2.2 channel, Kir2.1 channel, hetero-tetramer

* Equal contribution to first author

**Dedicated to the late Prof. Dr. Frank Lehmann-Horn who faithfully contributed to this work until his death on May 8th, 2018. We hereby thank him for his constant support and his continued optimism in the research field of ion channelopathies.

Address for correspondence: Marius Kuhn, Genetikum, Wegenerstraße 15, 89231 Neu-Ulm, Germany. E-mail: Kuhn@genetikum.de
Patients and methods

Patients

Informed consent was obtained from the proband with hypokalemic PP, and was already given for an additional 263 PP patients who were referred earlier for genetic consultation. Of the latter, 29 had FPP, 25 had TPP, and 209 had SPP. Clinical diagnosis was based on patient history provided by the referring physician. PP was diagnosed if, additionally, a parent, a sibling, or an offspring of the patient were clinically affected. TPP was diagnosed if there was concomitant hyperthyroidism present, and SPP was diagnosed for isolated cases. All patients had been tested negative for known pathogenic variants in \( SCN4A \), \( CACNA1S \), \( KCNJ2 \), and \( KCNJ18 \) genes. All procedures were approved by the Ethics Committee of Ulm University.

Exome sequencing

To determine the genetic cause of hypokalemic SPP in the proband, DNA was enriched with the SureSelectXT V5 exome kit (Agilent Technologies) and sequenced on a HiSeq 2500 Illumina sequencer. About 195 million paired reads of 100 bp length were produced. Reads were de-multiplexed with Casava version 1.8.2 (Illumina) and adapter sequences removed with Skewer version 0.1.116. Trimmed reads were mapped with Burrows-Wheeler Aligner version 0.7.2 (6) against the human reference genome hg19 (UCSC), yielding an average coverage of 155. Variant calling was performed using VarScan version 2.3.5 and Samtools version 0.1.18 (7). Calls were annotated using the Database of Single-Nucleotide Polymorphisms (dbSNP, www.ncbi.nlm.nih.gov/snp).

Variants potentially changing the protein were analysed further, i.e. non-synonymous SNPs, changes of initiation or stop codons, splicing variants, and in-frame or frameshifting insertions or deletions. Filtering was performed by excluding all variants more frequent than 0.5% as listed in dbSNP or UCSC Table Browser (www. genome.ucsc.edu) and requiring expression in skeletal muscle according to the Human Protein Atlas (320 genes, www.proteinatlas.org). The resulting variants were preliminarily interpreted using the protein prediction tools Polyphen-2 (www.genetics.bwh.harvard.edu/pph2), Mutation Taster (www.mutationtaster.org), and Sift (www.sift.jcvi.org).

Sanger sequencing

To confirm the presence of the identified \( KCNJ12 \) variant in the proband sample, the coding region of \( KCNJ12 \) was sequenced. Subsequently, \( KCNJ12 \) was sequenced in the remaining 263 DNA samples to check for recurrence in PP. The coding region of \( KCNJ12 \) was amplified using a gene-specific nested polymerase chain reaction (PCR) with two specific primers (forward: CCAGACATGCTGTGCTCTCTGTGTT; reverse: GGGGCCTTCCCCAGCCCG). The resulting products were sequenced using the forward-primer: (CCAGACATGTGCTCTCTCTGTGTT/CTGGCCCGTAGATGCTGCTCATC/GCCCGTGGTGGGCGCTGAC/GCCAATGAGATCCTGTGGGTCAC). Potential pathogenicity of the variants was preliminarily interpreted using the prediction tools Polyphen-2, Mutation Taster, and Sift. Additionally, to exclude mapping problems of the exome sequencing in the proband sample, the coding region of the known PP gene \( KCNJ18 \) was sequenced in the proband sample using the gene-specific nested PCR technique previously described (8).

Electrophysiological study

For functional expression of the identified variants, the human \( KCNJ12 \) subunit was sub-cloned into the pcDNA3.1 vector and site-directed mutagenesis of base changes coding for p.Thr140Met, p.Gly419Ser, p.Cys75Tyr, and p.Ile283Val variants was performed by an external lab (GATC Biotech). The human \( KCNJ12 \) subunit was cloned into the pcDNA3.1 vector by the same external lab. Whole-cell patch clamp recordings were performed after transient transfection of human tsA201 cells with \( KCNJ12 \) (0.2 μg) and pEGFP (0.05 μg) or, in co-expression studies, \( KCNJ12 \) (0.1 μg) with \( KCNJ12 \) (0.1 μg) and pEGFP (0.05 μg). Transfected cells were identified by GFP fluorescence. Potassium currents were recorded without leak subtraction after partial series resistance compensation (~85%) using an Axapath 200B amplifier (Molecular Devices). The pipette resistance was approximately 1.5 MΩ after filling with internal solution containing (in mM): Potassium gluconate 110, KCl 20, HEPES 10, EGTA 10, MgCl\(_2\)\( \cdot \)H\(_2\)O 1, Na\(_2\)ATP 5, glucose 5. The external solution contained (in mM): NaCl 117, KCl 30, CaCl\(_2\)\( \cdot \)2H\(_2\)O 2, MgCl\(_2\)\( \cdot \)H\(_2\)O 1, glucose 5, NaHCO\(_3\) 2, HEPES 10. In some experiments, external KCl was reduced to 5mM and NaCl increased to 142 mM. The pH was adjusted to 7.3 and 7.4 for external and internal solutions, respectively, and osmolarity was ~300 mOsm. Data are presented as mean ± standard error of the mean (SEM). Student’s t-tests were applied for statistical evaluation with significance levels set to p < 0.05.

Fluorescence imaging

To compare trafficking of wildtype channels to the p.Thr140Met variant, coding Kir2.2 regions were
sub-cloned into pEGFP vectors whereby EGFP was fused to the N-terminus of the region by an external lab (GATC Biotech). Transfected tsA cells cultured on 11 mm glass cover slips were fixed with paraffin, images were taken with fixed exposure time on an Axioskop 2 microscope with AxioCamMR3 and EC Plan-Neofluar 40x/1.30 oil lens (Zeiss), and the GFP detection was filtered as for Alexa 488. Membrane areas over the cytoplasm of the cells and background were analyzed as mean gray values with ImageJ. For quantification, background values were subtracted from the membrane values for each cell.

**Molecular modelling**

The crystal structure of a prokaryotic inwardly rectifying Kir channel (KirBac 3.1) was used as template for homology modelling of mammalian KCNJ12 and KCNJ2 (9). Clustal amino acid alignment of mammalian Kir channels encoded by KCNJ1-15, the Gallus gallus Kir2.2 channel, and KirBac3.1 channels was used in the production of homology models of human wildtype (WT) Kir2.1, WT Kir2.2, and variant p.Thr140Met Kir2.2. For these models, we used the structure file 4lp8.pdb (KirBac3.1)9 as template in MODELLER. Potassium ion coordinates were saved for the A chain in the Kir2.2 model, and tetramers of Kir2.2-Kir2.1 were constructed. Tetrameric models were then equilibrated to relieve subunit clashes and allowed to reach an energy minimum, with Chimera (10). The energy minimized tetramers were used to visualize the distribution of potassium ions with respect to the selectivity filter.

The quantitative impact of the p.Thr140Met variant was assessed with molecular dynamics (MD) simulations. Equilibrated models of KirWT2.2-KirWT2.1 or KirT140M2.2-KirWT2.1 (equimolar ratio of Kir2.2 and Kir2.1) were incorporated into POPC (1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine) lipid bilayers, solvated with TIPW water molecules and 0.2M KCl, and equilibrated for lipid and protein minimization, using VMD (visual molecular dynamics). Simulations were run in NAMD (not another molecular dynamics) with application of a CHARMM force field with Langevin dynamics at -600 mV. Trajectories of distance between the carboxyl of Glu139 and Thr140 (WT) or Met140 (variant) were calculated using the PLUMED plug-in, and trajectories of hydrogen bonding between Glu139 and Ile144 of the selectivity filter motif (TIGYG) were calculated using the H-bonding plug-in of VMD. Hydrogen bonding between analogous pairs is a critical step in early permeation of K+ ions through the selectivity filter in KcsA (11).

**Results**

**Proband phenotype**

The phenotype description of the proband is based on the medical file excerpts sent by the referring physician with the patient’s consent. The proband did not volunteer further information and denied additional examination and biopsy. He experienced only two documented episodes of quadriplegic weakness in his life, at age 18 and 30 years, both lasting 12 hours. During the second, serum potassium level was 1.88 mmol/L and potassium administration relieved the symptoms. Thyroid hormones levels were normal. The patient reported no cardiac arrhythmia and no dysmorphic features as would be typical for Andersen-Tawil syndrome. No relatives were known to be affected by PP. We classified the phenotype as very mild, hypokalemic SPP.

**Exome sequencing**

Altogether, 83,246 variants were detected in the sample of the proband, including redundant listings of the same variant in different splice isoforms. Elimination of intronic and synonymous changes reduced the number of variants including redundancies down to 17,880. Filtering by allele frequencies for variants more rare than 0.5% reduced the number of variants to 2,685. Filtering for muscle-specific expression (i.e. the 320 muscle specific genes according the Human Protein Atlas) and eliminating the redundant listings left 31 variants. These were preliminarily interpreted using Polyphen2, MutationTaster, and Sift (Table 1). Since these programs cannot interpret consequences of splicing variants, the two identified splice variants could not be analysed further. Of the remaining variants, only three were predicted to be linked to disease by at least two of the prediction programs: a KCNJ12 variant c.419C > T coding for p.Thr140Met in the Kir2.2 channel, a PRKCC variant c.685G > A coding for p.Asp229Asn in protein kinase C theta, and a TTN variant c.47828C > T coding for p.Thr15943Ile in titin. All three of these variants were present in a heterozygous state. None of the three variants have been, to our knowledge, reported to be associated to disease in the literature. Since all hitherto known causative PP genes encode ion channels, we opted to further study only the KCNJ12 variant.

**Sanger sequencing**

The presence of the heterozygous c.419C > T base change in KCNJ12 coding for p.Thr140Met in Kir2.2 was confirmed using Sanger sequencing (Fig. 1, top). Since a homologous p.Thr140Met in Kir2.6 encoded by KCNJ18 was reported previously (12), we confirmed absence of
the corresponding homologous c.419C > T base change in the KCNJ18 gene by Sanger Sequencing to exclude mapping problems of the exome analysis (Fig. 1, bottom). To test the possibility of the KCNJ12 gene being generally linked to PP, we sequenced 263 PP samples in KCNJ12 using the Sanger technique. No changes were detected in 249 samples; eleven samples had synonymous SNP (coding for 1x p.Arg214Arg, 8x p.Asp61Asp 1x p.Ser266Ser, 1x p.Asp291Asp); and three samples each had a different non-synonymous base change. The latter were: c.1255G > A coding for p.Gly419Ser (rs772629809) with an allele frequency of 0.000217 (consistently predicted to be benign), the not yet described c.224G > A coding for p.Cys75Tyr (consistently predicted to be pathogenic), and c.847A > G coding for p.Ile283Val (1x predicted to be pathogenic, 2x predicted to be benign) (Table 2).

The phenotypes for the three SPP cases with non-synonymous variants were briefly: i) for the p.Cys75Tyr carrier: onset at age 18, yearly quadriplegic episodes, ictal potassium of 1.5mM, episodes triggered by diarrhoea, fever, and sports, ii) for the p.Ile283Val carrier: onset at age 52, small fibre neuropathy, muscle jerking, cramps, myalgia, intermittent hypokalaemia with morning weakness lasting minutes, and iii) for the p.Gly419Ser carrier: two episodes in lifetime at age 22 and 28 lasting three hours, having concomitant myalgia, and being triggered by cortisol administration.

| Gene       | Base change | Protein change | SNP            | Allele frequency | Polyphen2 | Mutation taster | Sift       | Phenotype summary                                                                 |
|------------|-------------|----------------|----------------|------------------|-----------|-----------------|------------|----------------------------------------------------------------------------------|
| ACTN3      | c.2385C > G | p.Asp795Glu    | n.a.           | n.a.             | Benign    | Pseudogene      | n.a.       |                                                                                  |
| AGBL1      | c.774dupAGATGA | p.Glu258_Asp259dup | rs775629809    | 0.00017          | n.a.      | Benign Polymorphism | n.a.       |                                                                                  |
| CLIC5      | c.237A > T  | p.Arg79Ser     | rs41271277     | 0.002805          | Benign    | Polymorphism    | Tolerated  |                                                                                  |
| FHL3       | c.331 + 7G > C | splice variant | rs4570384      | 0.000594          | n.a.      | n.a.            | n.a.       |                                                                                  |
| HRC        | c.1001G > A | p.Gly334Asp    | rs796956072    | n.a.             | Benign    | Polymorphism    | Tolerated  |                                                                                  |
| HRC        | c.992C > A  | p.Ala331Asp    | rs763482766    | 0.000017          | Benign    | Polymorphism    | Tolerated  |                                                                                  |
| HRC        | c.986T > A  | p.Val329Asp    | rs138152757    | 0.000042          | Benign    | Polymorphism    | Tolerated  |                                                                                  |
| HRC        | c.744T > A  | p.Asp248Glu    | n.a.           | n.a.             | Benign    | Polymorphism    | Tolerated  |                                                                                  |
| HRC        | c.738T > A  | p.Asp246Glu    | n.a.           | n.a.             | Benign    | Polymorphism    | Tolerated  |                                                                                  |
| HRC        | c.730G > A  | p.Glu244Lys    | rs77526358     | 0.000817          | Benign    | Polymorphism    | Tolerated  |                                                                                  |
| HRC        | c.722A > G  | p.Gln241Arg    | rs773435857    | 0.000784          | Benign    | Polymorphism    | Tolerated  |                                                                                  |
| HRC        | c.703G > A  | p.Gly235Ser    | rs760105084    | 0.000746          | Benign    | Polymorphism    | Tolerated  |                                                                                  |
| HRC        | c.689G > A  | p.Gly230Glu    | rs756913154    | 0.000690          | Benign    | Polymorphism    | Tolerated  |                                                                                  |
| IGFN1      | c.4646C > T | p.Thr1549Arg   | rs199718718    | n.a.             | n.a.      | Polymorphism    | Tolerated  |                                                                                  |
| IGFN1      | c.471SC > T | p.Ala1572Val   | rs201241861    | 0.000090          | n.a.      | Polymorphism    | Tolerated  |                                                                                  |
| IGFN1      | c.4728G > A | p.Met1576Ile   | n.a.           | n.a.             | Polymorphism | Tolerated       | n.a.       |                                                                                  |
| IGFN1      | c.4747A > G | p.Ser1583Gly   | rs199574248    | n.a.             | n.a.      | Polymorphism    | Tolerated  |                                                                                  |
| IGFN1      | c.4823T > C | p.Val1608Ala   | rs201505263    | n.a.             | n.a.      | Polymorphism    | Tolerated  |                                                                                  |
| IGFN1      | c.4828G > A | p.Glu1610Lys   | rs71524455     | 0.000962          | n.a.      | Polymorphism    | Tolerated  |                                                                                  |
| IGFN1      | c.4855G > A | p.Gly1619Ser   | rs189258058    | n.a.             | n.a.      | Polymorphism    | Tolerated  |                                                                                  |
| IGFN1      | c.5160G > A | p.Met1720Ile   | rs200673977    | 0.000787          | n.a.      | Polymorphism    | Tolerated  |                                                                                  |
| IGFN1      | c.6016G > A | p.Glu2006Lys   | rs12729404     | 0.000116          | Benign    | Polymorphism    | Tolerated  |                                                                                  |
| IGFN1      | c.6024A > G | p.Ile2008Met   | rs12728986     | 0.000114          | Benign    | Polymorphism    | Tolerated  |                                                                                  |
| IGFN1      | c.6043G > A | p.Gly2015Ser   | rs796090138    | n.a.             | n.a.      | Polymorphism    | Tolerated  |                                                                                  |
| KCNJ12     | c.419C > T  | p.Thr140Met    | rs536297311    | 0.000056          | Probably damaging | Disease causing | Tolerated  |                                                                                  |
| LRR14B     | c.310C > T  | p.Arg104Cys    | n.a.           | n.a.             | Benign    | Polymorphism    | Tolerated  |                                                                                  |
| MAFA       | c.621dupCA  | p.His208del    | rs141816879    | n.a.             | n.a.      | Polymorphism    | n.a.       |                                                                                  |
| PPP1R3A    | c.1428C > A | p.Asn476Lys    | rs2974944      | 0.001129          | Benign    | Polymorphism    | Tolerated  |                                                                                  |
| PRKDCQ     | c.685G > A  | p.Asp229Asn    | rs34524148     | 0.001052          | Probably damaging | Disease causing | Tolerated  |                                                                                  |
| TTN        | c.47828C > T | p.Thr1594Ile   | rs776113556    | 0.000008          | Probably damaging | Disease causing | n.a.       |                                                                                  |
| TTN        | c.10361-5delT | Splice variant | rs586651353    | n.a.             | n.a.      | n.a.            | n.a.       |                                                                                  |

n.a. = not available.
The prediction results (Tables 1, 2) suggest i) that p.Gly419Ser would not be expected to cause any effects, ii) that the expectation for p.Ile283Val is unclear, and iii) that p.Cys75Tyr and p.Thr140Met would be expected to produce relevant changes in channel function. To test whether the prediction programs correctly assessed the disease-causing potency of the variants and, more specifically, to test whether p.Thr140Met may contribute to the SPP phenotype in the proband, we performed whole cell patch clamp studies on the four non-synonymous Kir2.2 variants.

**Electrophysiology and fluorescence imaging**

Kir currents were elicited from a holding potential of 0 mV in 10 mV-voltage steps of 100ms duration from hyperpolarized potentials – 80 mV to + 40 mV. In 30 mM external KCl, typical rectifier Kir currents were recorded from expression of Kir2.2-WT and the three variants p.Cys75Tyr, p.Ile283Val, and p.Gly419Ser. In contrast, no endogenous Kir currents were detected in untransfected cells or in cells expressing p.Thr140Met. However, when WT was co-expressed with p.Thr140Met, typical Kir currents could be observed (Fig. 2A).

These findings could indicate, among other possibilities, that p.Thr140Met channels are not synthesized, not inserted into the membrane, or not functional. To assess the subcellular localization of the p.Thr140Met channels in comparison with Kir2.2-WT, we performed fluorescence imaging. Both channel types were expressed uniformly on the plasma membrane, with gray levels of WT vs p.Thr140Met being 16.17 ± 0.95 vs 13.49 ± 1.11 (p = 0.08, n = 18-19) (Fig. 2B). This finding indicates that p.Thr140Met channels are observed at levels similar to WT in the plasma membrane 24 hours post-transfection which means that protein synthesis, trafficking, and membrane insertion are intact. Therefore, the effect of p.Thr140Met is more likely to be Table 2. Sanger sequencing KCNJ12 in PP.

| Base change | Protein change | SNP | Allele frequency | Poly-Phen2 | Mutation tester | Sift |
|-------------|----------------|-----|-----------------|------------|----------------|------|
| c.224G > A  | p.Cys75Tyr     | n.a.| n.a.            | Probably damaging | Disease causing | Damaging |
| c.847A > G  | p.Ile283Val    | n.a.| n.a.            | Benign     | Disease causing | Tolerated |
| c.1255G > A | p.Gly419Ser    | rs77266866 | 0.00077         | Benign     | Polymorphism   | Tolerated |

n.a. = not available

Figure 1. Sanger sequencing proband. Electropherogram of both genes, KCNJ12 (top) and KCNJ18 (bottom). The presence of a heterozygous c.419C > T base change coding for p.Thr140Met in the coding region of KCNJ12 was confirmed using Sanger sequencing (red box). In KCNJ18, no base change was identified at this position. Additionally, two positions were marked (black boxes) to highlight the differences in wildtype sequences of these two genes in this highly homologous region proving the specificity of our amplification.
due to a direct effect on channel function, a possibility that we focused further on using electrophysiology.

Plotting of the obtained current peaks against the voltage revealed almost linear current-voltage relationships (Fig. 2C). Conductances were calculated from the steepness of the current-voltage relationship in the voltage range from −70 mV to −40 mV. Conductances for the inward currents were 288.28±49.11 nS/pF for WT (n = 19), 308.49 ± 77.84 nS/pF for p.Gly419Ser (n = 8, p = 0.82), 275.36 ± 44.47 nS/pF for p.Ile283Val (n = 15, p = 0.85), 220.76 ± 37.39 nS/pF for p.Cys75Tyr (n = 15, p = 0.3), 2.67 ± 0.79 nS/pF for p.Thr140Met (n = 16, p < 0.001), and 216.47 + 64.36 for Kir2.2-WT+Kir2.2-p.Thr140Met (n = 10, p = 0.39). Of these, only the conductance of p.Thr140Met alone differed from WT significantly.

To further study the voltage range around the resting membrane potential of skeletal muscle, extracellular KCl was decreased to 5 mM and the starting potential adjusted to −140 mV. Plotting of these current peaks against the voltage revealed linear to saturated current-voltage relationships and reduced current densities compared to WT (Fig. 2D). Conductances for the inward current were 840.48 ± 98.62 nS/pF for WT (n = 10), 530.26 ± 82.47 nS/pF for p.Gly419Ser (n = 11, p = 0.19), 523.08 ± 62.29 nS/pF for p.Ile283Val (n = 11, p = 0.06), 614.29 ± 73.16 nS/pF for p.Cys75Tyr (n = 11, p = 0.18), and 1.51 ± 0.43 nS/pF for p.Thr140Met (n = 15, p < 0.001). This suggests that only p.Thr140Met reduced channel function.

Since the homologous Kir2.1 is the main skeletal muscle potassium channel maintaining the resting

---

**Figure 2. Functional expression.** Functional characterization of Kir2.2-WT and four missense variants expressed in tsA 201 cells. A) Representative current traces. Note that p.Thr140Met channels do not produce a current. B) Fluorescence image of the tsA 201 cell expressing WT and p.Thr140Met Kir2.2 fusion proteins with GFP (Left). Mean grey values from the membrane areas after subtraction of background showed comparable signal intensity between WT (n = 18) and p.Thr140Met (n = 19) (Right). C) Normalized current-voltage relationships for untransfected cells (n = 9), WT (n = 19), p.Cys75Tyr (n = 15), p.Thr140Met (n = 16), p.Ile283Val (n = 15), p.Gly419Ser (n = 8) and Kir2.2-WT+Kir2.2-p.Thr140Met (n = 10) recorded in 30mM external K+. D) Normalized current-voltage relationships for WT (n = 10), p.Cys75Tyr (n = 11), p.Thr140Met (n = 15), p.Ile283Val (n = 11) and p.Gly419Ser (n = 11) recorded in 5mM external K+. Data are shown as means ± SEM.
membrane potential, along with Kir2.2 (13) we investigated the effects of the variants on heteromeric Kir2.2-Kir2.1 channels by co-transfecting the two plasmids at an equimolar ratio. As expected by the literature (14), WT Kir2.1/WT Kir2.2 co-expression showed a significantly higher current density at 5 mM extracellular KCl at -130 mV (–737.06 ± 113.27 pA/pF, n = 14) compared with expression of WT Kir2.1 alone (–491.82 ± 48.18 pA/pF, n = 17, p = 0.04) which indicates formation of functional hetero-tetramers in our experimental conditions (Fig. 3A). Plotting of the obtained current peaks against the voltage revealed linear to saturated current-voltage relationships (Fig. 3B). Conductances for the inward current were 1036.91 ± 151.97 nS/pF for WT (n = 14), 529.66 ± 75.37 nS/pF for p.Gly419Ser (n = 16, p = 0.01), 624.91 ± 110.25 nS/pF for p.Ile283Val (n = 17, p = 0.03), 552.36 ± 92.89 nS/pF for p.Cys75Tyr (n = 17, p = 0.01), and 134.11 ± 48.99 nS/pF for p.Thr140Met (n = 19, p < 0.001). This suggests that all variants reduced co-expressed Kir2.1 function to some degree with p.Thr140Met being the most potent which may elicit a so-called dominant-negative effect on Kir2.1 by reducing conductance by 87% in our experiment.

Molecular modelling

To confirm a dominant negative effect of Kir2.2 with p.Thr140Met on WT Kir2.1, we created three-dimensional models of Kir2.2-Kir2.1 hetero-tetramers (Fig. 4A, B). These were equilibrated for energy minimization using Chimera, and compared for the WT Kir2.2-Kir2.1 tetramer, p.Thr140Met Kir2.2-WT Kir2.1 tetramer (2:2) and for p.Thr140Met Kir2.2-WT Kir2.1 chains. For the Kir WT 2.2-2.1 tetramer in equimolar model ratio, energy minimization resulted in a re-distribution of potassium ions towards the putative binding sites in the pore helix of Kir 2.2 compatible with a higher maximal current of the hetero-tetramer (Fig. 4C). For the Kir p.Thr140Met 2.2-Kir WT2.1 tetramer in equimolar model ratio, re-distribution of potassium ion was minimal (Fig. 4D), and this effect was even more pronounced when 3 Kir p.Thr140Met 2.2 chains were used in construction of the tetramer (Fig. 4E). These findings support the functional results showing that p.Thr140Met reduces the maximal current of the hetero-tetramer.

In order to quantify the effect of the variant, molecular dynamics simulations for the WT Kir2.2-Kir2.1 tetramer versus p.Thr140Met Kir2.2-WT Kir2.1 tetramer (2:2) were performed. They revealed two significant differences between the WT Kir2.2-Kir2.1 model (Fig. 5A) and Thr140Met Kir2.2-Kir2.1 model (Fig. 5B). The first was that the distance between center of mass at the distal carbon for adjacent residues in the pore helix of Glu139 and Thr140 (WT) or Met140 (variant) was significantly greater for the WT model (8.09 ± 0.43 Å) compared to the Thr140Met model (5.39 ± 0.52 Å, p ≤ 0.05, Fig. 5C). The second was that the H-bonding between Glu139 and Ile144 of the TIGYG selectivity filter was observed in 37.2% of frames for the WT model, but in no frames at all for the Thr140Met model (Fig. 5D). It is quite possible that the shorter distance between side chains of the Glu139 and Met140 compared to that for Glu139 and Thr140 may contribute to the loss of hydrogen bonding in the Thr140Met model.
Based on the Sanger sequencing data, it is clear that non-synonymous Kir2.2 variants are infrequent; we found 4 in 264 patient samples (1.5%) a frequency similar to a previous study of the homologous channel Kir2.6 which detected 10 variants in 263 patient samples (3.8%) (8). Three of the variants, p.Gly419Ser, p.Ile283Val, and p.Cys75Tyr, are all located in cytoplasmic regions of the Kir2.2 channel. p.Gly419Ser is a known benign polymorphism named rs77266866 (dbSNP database, www.ncbi.nlm.nih.gov/snp/) which slightly depressed co-expressed Kir2.1. The two novel variants, p.Ile283Val, and p.Cys75Tyr, presented with functional effects of a similar degree. Therefore, all three variants may be interpreted as benign functional polymorphisms according to Jurkat-Rott and Lehmann-Horn 2005 (15). In contrast, p.Thr140Met is located in a transmembrane pore-forming alpha helix close to the selectivity filter (amino acid residues 143-148). It produced a loss of Kir2.2 function and suppressed co-expressed WT Kir2.1. This may indicate a susceptibility or potentially pathogenic variant.

The prediction programs were not reliable in determining the functional effects since of the two variants which both were consistently predicted to be pathogenic, p.Cys75Tyr and p.Thr140Met, only one had significant functional effects. In contrast, three variants had comparable function but very different prediction results: p.Gly419Ser which was consistently predicted to be benign and the two novel variants, p.Ile283Val and p.Cys75Tyr, one of which was consistently predicted to be pathogenic. This assessment is in agreement with previous studies on the quality of prediction programs in ion channelopathies which found reasonable sensitivities ranging from ~70-90% but low specificities of ~15-50% depending on channel type and protein regions within the channels (16, 17).

Our data show that the loss of function of p.Thr140Met Kir2.2 is not due to a trafficking defect but results from an alteration of the ion pore conductance. Together with the dominant negative effect on the main skeletal muscle rectifying potassium channel, Kir2.1, the functional effects are very similar to those of the PP Mutations in Kir2.6 which also display a loss of function and suppress co-
expressed Kir2.1 (12, 18). Additionally, the same amino acid change, i.e. p.Thr140Met, in the highly homologous Kir2.6 channel has been shown to cause a similar phenotype, TPP (12), which supports the notion of susceptibility or potential pathogenicity of p.Thr140Met in Kir2.2.

As to the dominant negative effect on Kir2.1, loss of function mutations in the encoding KCNJ2 gene are known to cause Andersen-Tawil Syndrome, a PP phenotype with the additional features cardiac arrhythmia and facial dysmorphia (5). However, our patient did not have such symptoms nor did the TPP patients with Kir2.6 mutations described previously (12). To clarify this conundrum, we compared public data of quantitative tissue-specific expression patterns. According to the Genotype Tissue Expression Consortium (www.gtexportal.org), the following RNA expression levels in reads per kilobase per million mapped reads have been found for KCNJ12 vs KCNJ2: for skeletal muscle 12.3 vs 1.0, for heart 2.9 vs 2.3, and for skin 3.6 vs 0.9. Data from another source, the Human Protein Atlas (www.proteinatlas.org), lists the following transcripts per million: for skeletal muscle 23.1 vs 3.3, for heart 3.9 vs 6.3, and for skin 2.1 vs 5.6. The Fantom5 Consortium (www.fantom.gsc.riken.jp) has published the following expression levels in tags per million: for skeletal muscle 19.1 vs 8.1, for heart 7.4 vs 23.9, and for skin no data is available. All three sources agree that KCNJ12 ex-
pression in skeletal muscle is at least two times larger than KCNJ2. This is not the case for heart and skin.

Possible phenotypes may be suggested by knockouts. While KCNJ2 knockout mice die within hours after birth due to severe dysmorphia (cleft palate) and show no Kir currents in arterial myocytes, KCNJ2 knockouts are viable and fertile and without dysmorphia (19). Suppression of Kir2.1 in heart leads to reduction of the cardiac Kir current by 95% (20). Taken together, expression levels and knockout data suggest that Kir2.2 mutations are most likely, if not exclusively, to cause muscle symptoms and not dysmorphia or cardiac arrhythmia.

Assuming a relative abundance of KCNJ2 to KCNJ2 of 2:1, there would be an equimolar ratio of WT Kir2.2 to p.Thr140Met Kir 2:2 to WT Kir2.1, i.e. of 1:1:1. Heterotetramers with none, one, or several p.Thr140Met may be present. Our molecular modelling demonstrated that the incorporation of an increasing number of Kir2.2 p.Thr140 in heterotetramers with Kir2.1 decreased the movement of potassium ions towards their binding sites in the pore helix which directly results in current reduction. Quantification by molecular dynamics simulations demonstrated that the incorporation of Kir2.2 p.Thr140 in heterotetramers with Kir2.1 resulted in loss of formation of hydrogen bonding between Glu139 and Ile144 of the selectivity filter. This interaction is important in early permeation steps in KcsA channels (11), supporting the hypothesis that current reduction in heterotetramers containing the p.Thr140Met Kir 2:2 variant may be, at least partly, the consequence of the observed reduction in hydrogen bonding. Whether or not the current reduction is enough to reduce the total inward Kir current sufficiently to cause PP determines the difference between pathogenic variant and susceptibility (15).

Additionally, there may be genetic background factors to take into account. In the proband with p.Thr140Met in Kir2.2, there were two additional, unknown, non-synonymous, possibly pathogenic, heterozygous variants: one in PRKCG encoding protein kinase C theta (PKCθ) and one in TTN encoding titin. Both have previously not been linked to PP, but may still contribute to the phenotype of the proband. Titin mutations are known to cause multiple other diseases of heart and skeletal muscle; namely several cardiomyopathies, limb-girdle dystrophy type 2, proximal myopathy with respiratory involvement, Salih myopathy, and tardive tibial muscular dystrophy (21, 22) and, therefore, titin variants could contribute to the manifestation of muscle weakness. For PKCθ, even though it has not been associated to disease at all, it is quite important for regulation of skeletal muscle function. PKCθ phosphorylates and thereby reduces the current amplitude of the muscular chloride channel CIC-1 (23) which helps muscle to uphold muscle excitability during exercise (24). An increased PKCθ could mimic the pathogenic mechanism underlying the skeletal muscle disorder of myotonia congenita which is caused by muscle hyperexcitability due to decreased CIC-1 current (25). Alternatively, an inhibition of Protein kinase C – which may be expected to a. o. increase CIC-1 current – improves muscle regeneration in a mouse model of Duchenne muscular dystrophy (26) and could lessen the severity of a PP phenotype.

Taken together, the sporadic occurrence of SPP suggests that the pathogenic potency of Kir2.2 variants may be dependent on additional factors such as individual genetic background (i.e. co-existing variants in PRKCG and TTN) or epigenetic phenomena. Therefore, we conclude that Kir2.2 p.Thr140Met may be most safely interpreted as a SPP susceptibility variant and it should be included in the genetic testing scheme for diagnosing SPP.

Acknowledgements

This study was supported by the non-profit Hertie Foundation, the German Federal Ministry of Research (BMBF IonNeurONet), the DGM German Muscle Disease Society, Taro Pharma, and NIH R15 NS09357901-A1. We thank Landon Bayless-Edwards (ISU) for invaluable assistance with computations from MD simulations.

References

1. Matthews E, Silwal A, Sad R, et al. Skeletal muscle channelopathies: rare disorders with common pediatric symptoms. J Pediatr 2017;188:181-5.
2. Cannon SC. Channelopathies of skeletal muscle excitability. Compr Physiol 2015;5:761-90.
3. Jurkat-Rott K, Groome JR, Lehmann-Horn F. Pathophysiological role of omega pore current in channelopathies. Front Neuropharmacol 2012;3:1-15.
4. Spillane J, Kullmann DM, Hanna MG. Genetic neurological channelopathies: molecular genetics and clinical phenotypes. J Neurol Neurosurg Psychiatry 2016;87:37-48.
5. Statland JM, Tawil R, Venance SL, Andersen-Tawil syndrome. In: Adam MP, Ardingher HH, Pagon RA, et al., Eds. GeneReviews®. Seattle (WA): University of Washington, 1993-2018.
6. Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 2009;25:1754-60.
7. Li H, Handsaker B, Wysoker A, et al. 1000 genome project data processing subgroup. The sequence alignment/map format and SAMtools. Bioinformatics 2009;25:2078-9.
8. Kuhn M, Jurkat-Rott K, Lehmann-Horn F. Rare KCNJ18 variants do not explain hypokalaemic periodic paralysis in 263 unrelated patients. J Neurol Neurosurg Psychiatry 2016;87:49-52.
9. Zubcevic L, Bavro VN, Muniz JRC, et al. Control of KirBac3.1 potassium channel gating at the interface between cytoplasmic domains. J Biol Chem 2014;289:143-51.
10. Pettersen EF, Goddard TD, Huang CC, et al. UCSF Chimera – a visualization system for exploratory research and analysis. J Comput Chem 2004;25:1605-12.
11. Berneche S, Roux B. A gate in the selectivity filter of potassium channels. Structure 2005;13:591-600.
12. Ryan DP, da Silva MR, Soong TW, et al. Mutations in potassium channel Kir2.6 cause susceptibility to thyrotoxic hypokalemic periodic paralysis. Cell 2010;140:88-98.
13. DiFranco M, Yu C, Quiñonez M, et al. Inward rectifier potassium currents in mammalian skeletal muscle fibres. J Physiol 2015;593:1213-38.
14. Panama BK, McLerie M, Lopatin AN. Functional consequences of Kir2.1/Kir2.2 subunit heteromerization. Pflugers Arch 2010;460:839-49.
15. Jurkat-Rott K, Lehmann-Horn F. Muscle channelopathies and critical points in functional and genetic studies. J Clin Invest 2005;115:2000-9.
16. Leong IU, Stuckey A, Lai D, et al. Assessment of the predictive accuracy of five in silico prediction tools, alone or in combination, and two metaservers to classify long QT syndrome gene mutations. BMC Med Genet 2015;16:34.
17. Flanagan SE, Patch AM, Ellard S. Using SIFT and PolyPhen to predict loss-of-function and gain-of-function mutations. Genet Test Mol Biomarkers 2010;14:533-7.
18. Cheng CJ, Lin SH, Lo YF, et al. Identification and functional characterization of Kir2.6 mutations associated with non-familial hypokalemic periodic paralysis. J Biol Chem 2011;286:27425-35.
19. Zaritsky JJ, Eckman DM, Wellman GC, et al. Targeted disruption of Kir2.1 and Kir2.2 genes reveals the essential role of the inwardly rectifying K(+) current in K(+) mediated vasodilation. Circ Res 2000;87:160-6.
20. McLerie M, Lopatin AN. Dominant-negative suppression of I(K1) in the mouse heart leads to altered cardiac excitability. J Mol Cell Cardiol 2003;35:367-78.
21. Chauveau C, Rowell J, Ferreiro A. A rising titan: TTN review and mutation update. Hum Mutat 2014;35:1046-59.
22. Savarese M, Sarparanta J, Vihola A, et al. Increasing role of Titin mutations in neuromuscular disorders. J Neuromuscul Dis 2016;3:293-308.
23. Camerino GM, Bouchê M, De Bellis M, et al. Protein kinase C theta (PKCθ) modulates the ClC-1 chloride channel activity and skeletal muscle phenotype: a biophysical and gene expression study in mouse models lacking the PKCθ. Pflugers Arch 2014;466:2215-28.
24. Riisager A, de Paoli FV, Yu WP, et al. Protein kinase C-dependent regulation of ClC-1 channels in active human muscle and its effect on fast and slow gating. J Physiol 2016;594:3391-406.
25. Imbrici P, Altamura C, Pessia M, et al. ClC-1 chloride channels: state-of-the-art research and future challenges. Front Cell Neurosci 2015;9:156.
26. Marrocco V, Fiore P, Benedetti A, et al. Pharmacological Inhibition of PKCθ counteracts muscle disease in a mouse model of Duchenne muscular dystrophy. EBioMedicine 2017;16:150-61.